Fluid Absorption and Blood DNA Changes During Bladder Tumor Removal Surgery
Looks at fluid absorbed during bladder tumor surgery and tumor DNA in blood.
Plain-language title generated from the registry record
Registry title: Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
Key facts
- Where
- Lanzhou, ChinaSee the site
Where in China
- The Second Hospital of Lanzhou UniversityLanzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhiping Wang
- Trial code
- NCT07589413
- Record updated
- 15 May 2026
- Original description
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis.Read full original descriptionShow less
A Predictive Model for Recurrence and Progression Risk After TURBT for Bladder Cancer on Intraoperative Irrigation Fluid Absorption Volume and Perioperative cfDNA Levels
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis.
The study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Patients will also be followed for postoperative recurrence, progression, metastasis, and other adverse oncological outcomes.
This study may provide preliminary evidence for understanding perioperative tumor-related molecular changes during TURBT and may help improve risk stratification, perioperative management, and postoperative follow-up strategies for patients with bladder cancer.
Inclusion: Age 18 years or older; Suspected or histologically confirmed urothelial carcinoma of the bladder; Scheduled to undergo TURBT; Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis; Availability of complete clinicopathological and perioperative data; Ability to provide informed consent and comply with study follow-up.
Exclusion: Previous radical cystectomy or systemic antitumor therapy before enrollment; Non-urothelial bladder malignancy confirmed by pathology; History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix; Serious uncontrolled intercurrent illness that may interfere with study participation, follow-up, or compliance, including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, severe psychiatric illness, or other conditions judged by the investigator to make participation unsuitable; Inadequate blood sample quality or insufficient DNA yield for mutation analysis; Pregnancy or breastfeeding.